Macimorelin is a synthetic non-peptide growth hormone secretagogue receptor (GHSR) agonist. It is approved for use in diagnosing adult growth hormone deficiency (AGHD). When administered orally, macimorelin stimulates the release of growth hormone (GH) from the pituitary gland. The primary clinical utility of macimorelin is to assess the functional integrity of the somatotropic axis, providing a diagnostic tool for AGHD. This condition can lead to various symptoms including altered body composition, reduced bone mineral density, and impaired quality of life. Traditional methods for diagnosing AGHD often involve complex and time-consuming stimulation tests, such as the insulin tolerance test (ITT), which carries risks and requires close medical supervision. Macimorelin offers a simpler, oral alternative to these more invasive tests. The diagnostic test involves measuring serum GH levels at specific time points after macimorelin administration. A peak GH level below a predefined cutoff indicates growth hormone deficiency. Its development represents a significant advancement in the diagnostic landscape for AGHD, offering improved convenience and safety for patients. (FDA label, EMA SmPC)
Deep dive
Tap a section to expand.
Known interactions
Category rule: supplement × medication
Note
Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).
Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.
Category rule: vitamin × medication
Note
Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).
Specific pairs are checked against a licensed source; confirm with your provider.
Frequently asked
Sources referenced
- U.S. Food and Drug Administration (FDA) label
- European Medicines Agency (EMA) Summary of Product Characteristics (SmPC)
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the medication category or studied for the same goals.